Stockhead on MSN33m
Dr Boreham’s Crucible: Did this ASX biotech hit unicorn status without significant hurdles? Of Coris not
The Coris FDA assent isn’t the first rodeo for Nanosonics, given its inaugural Trophon device has been commercialised since ...